- Amendments to the Claims -

1. (Currently amended) An inhaled combination of (a) a selective PDE4 inhibitor of the formula (I)



(I)

or a pharmaceutically acceptable salt ~~or solvate~~ thereof, wherein:

R^1 is H, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, (C_2-C_4) alkenyl, phenyl, -$N(CH_3)_2$, (C_3-C_6) cycloalkyl, (C_3-C_6) cycloalkyl(C_1-C_3) alkyl or (C_1-C_6) acyl, wherein the alkyl, phenyl or alkenyl groups may be substituted with up to two -OH, (C_1-C_3) alkyl, or -CF_3 groups or up to three halogens;

R^2 and R^3 are each independently selected from the group consisting of H, (C_1-C_{14}) alkyl, (C_1-C_7) alkoxy(C_1-C_7) alkyl, (C_2-C_{14}) alkenyl, (C_3-C_7) cycloalkyl, (C_3-C_7) cycloalkyl(C_1-C_2) alkyl, a saturated or unsaturated (C_4-C_7) heterocyclic$(CH_2)_n$ group wherein n is 0, 1 or 2, containing as the heteroatom one or two of the group consisting of oxygen, sulfur, sulfonyl, nitrogen and NR^4 where R^4 is H or (C_1-C_4) alkyl; or a group of the Formula (II):



(II)

wherein a is an integer from 1 to 5; b and c are 0 or 1; R^5 is H, -OH, (C_1-C_5) alkyl, (C_2-C_5) alkenyl, (C_1-C_5) alkoxy, (C_3-C_6) cycloalkoxy, halogen, -CF_3, -CO_2R^6, -$CONR^6R^7$, -NR^6R^7, -NO_2, or -$SO_2NR^6R^7$ wherein R^6 and R^7 are each independently H, or (C_1-C_4) alkyl; Z is -O-, -S-, -SO_2-, -CO- or -$N(R^8)$- wherein R^8 is H or (C_1-C_4) alkyl; and Y is (C_1-C_5) alkylene or (C_2-C_6) alkenylene optionally substituted with up to two (C_1-C_7) alkyl or (C_3-C_7) cycloalkyl groups; wherein each of the alkyl, alkenyl, cycloalkyl, alkoxyalkyl or heterocyclic groups may be substituted with 1 to 14~~, preferably 1 to 5,~~ (C_1-C_2) alkyl, CF_3, or halo groups; and

R^9 and R^{10} are each independently selected from the group consisting of H, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, (C_6-C_{10}) aryl and (C_6-C_{10}) aryloxy;
and (b) an adrenergic β2 receptor agonist.

2. (Currently amended) A combination <u>of</u> ~~as claimed in~~ claim 1 wherein R^1 is methyl, ethyl or isopropyl.

3. (Currently amended) A combination <u>of</u> ~~as claimed in~~ claim 1 ~~or claim 2~~ wherein R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_3-C_7) cycloalkyl, (C_3-C_7)cycloalkyl(C_1-C_6)alkyl or phenyl optionally susbtituted with 1 or 2 of the group consisting of H, -OH, (C_1-C_5) alkyl, (C_2-C_5) alkenyl, (C_1-C_5) alkoxy, halogen, trifluoromethyl, -CO_2R^6, -$CONR^6R^7$, -NR^6R^7, -NO_2 or -$SO_2NR^6R^7$ wherein R^6 and R^7 are each independently H or (C_1-C_4) alkyl.

4. (Currently amended) A combination <u>of claim 1</u> ~~as claimed in any one of the preceding claims~~ wherein the selective PDE4 inhibitor of the formula (I) is ~~selected from~~:

9-cyclopentyl-5,6-dihydro-7-ethyl-3-phenyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopenyl-5,6-dihydro-7-ethyl-3-(furan-2-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(4-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(3-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3-benzyl-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-propyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3,9-dicyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3-(*tert*-butyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methoxyphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(thien-2-yl)-9*H*-pyrazolo[3,4-*c*]1,2,4-triazolo[4,3-*a*]pyridine;

3-(2-chlorophenyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-iodophenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-trifluoromethylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine; ~~and~~ or
5,6-dihydro-7-ethyl-9-(4-fluorophenyl)-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine; or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

5. (Currently amended) A combination of ~~as claimed in~~ claim 4 wherein the selective PDE4 inhibitor of the formula (I) is ~~selected from~~ 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine ~~and~~ or 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-□]pyridine ~~and the~~ or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

6. (Currently amended) A combination of ~~as claimed in~~ any one of ~~the preceding~~ claims 1 - 5 wherein the adrenergic β2 receptor agonist is ~~selected from~~ salmeterol, formoterol ~~and the~~ or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

7. (Currently amended) A combination ~~as claimed in~~ of claim 1 wherein:
the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine, or a pharmaceutically acceptable salt ~~or solvate~~ thereof, and the adrenergic β2 receptor agonist is salmeterol, or a pharmaceutically acceptable salt ~~or solvate~~ thereof;
the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine, or a pharmaceutically acceptable salt ~~or solvate~~ thereof, and the adrenergic β2 receptor agonist is formoterol, or a pharmaceutically acceptable salt ~~or solvate~~ thereof;
the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine, or a pharmaceutically acceptable salt ~~or solvate~~ thereof, and the adrenergic β2 receptor agonist is salmeterol, or a pharmaceutically acceptable salt ~~or solvate~~ thereof; or
the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine, or a pharmaceutically acceptable salt ~~or solvate~~ thereof, and the adrenergic β2 receptor agonist is formoterol, or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

8. (Canceled)
9. (Canceled)

10. (Currently amended) ~~A~~ An inhalable pharmaceutical composition comprising a selective PDE4 inhibitor of the formula (I)~~, as defined in~~ of claim 1, an adrenergic β2 receptor agonist and a pharmaceutically acceptable excipient, diluent or carrier~~, for administration by the inhaled route in the treatment of an obstructive airways or other inflammatory disease~~.

11. (Canceled)
12. (Canceled)
13. (Canceled)

14. (Currently amended) A method of treating ~~of~~ an obstructive airways ~~or other inflammatory~~ disease comprising administering ~~simultaneously, sequentially or separately,~~ by the inhaled route, to a mammal in need of such treatment, an effective amount of a

selective PDE4 inhibitor of the formula (I), ~~as defined in~~ of claim 1, and an adrenergic β2 receptor agonist.

15. (Canceled)

16. (Currently amended) An inhalation device for simultaneous, sequential or separate administration of a selective PDE4 inhibitor of the formula (I), ~~as defined in~~ of claim 1, and an adrenergic β2 receptor agonist in the treatment of an obstructive airways or other inflammatory disease.

17. (Canceled)

18. (New) A pharmaceutical composition of claim 10 wherein the selective PDE4 inhibitor of the formula (I) is:

9-cyclopentyl-5,6-dihydro-7-ethyl-3-phenyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopenyl-5,6-dihydro-7-ethyl-3-(furan-2-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(4-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(3-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3-benzyl-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-propyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3,9-dicyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3-(*tert*-butyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methoxyphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(thien-2-yl)-9*H*-pyrazolo[3,4-*c*]1,2,4-triazolo[4,3-*a*]pyridine;

3-(2-chlorophenyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-iodophenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-trifluoromethylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine; or
5,6-dihydro-7-ethyl-9-(4-fluorophenyl)-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine; or a pharmaceutically acceptable salt thereof.

19. (New) A pharmaceutical composition of claim 18 wherein the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine or 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine or a pharmaceutically acceptable salt thereof.

20. (New) A pharmaceutical composition of claim 18 wherein the adrenergic β2 receptor agonist is selected from salmeterol, formoterol or a pharmaceutically acceptable salt thereof.

21. (New) A pharmaceutical composition of claim 18 wherein:
the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine, or a pharmaceutically acceptable salt thereof, and the adrenergic β2 receptor agonist is salmeterol, or a pharmaceutically acceptable salt thereof;
the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine, or a pharmaceutically acceptable salt thereof, and the adrenergic β2 receptor agonist is formoterol, or a pharmaceutically acceptable salt thereof;
the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine, or a pharmaceutically acceptable salt

thereof, and the adrenergic β2 receptor agonist is salmeterol, or a pharmaceutically acceptable salt thereof; or

the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine, or a pharmaceutically acceptable salt thereof, and the adrenergic β2 receptor agonist is formoterol, or a pharmaceutically acceptable salt thereof.

22. (New) A method of treating of an inflammatory disease in a mammal comprising administering, by the inhaled route, to a mammal in need of such treatment, an effective amount of a selective PDE4 inhibitor of the formula (I) of claim 1, and an adrenergic β2 receptor agonist.

23. (New) A method of claim 14 or 22 wherein the selective PDE4 inhibitor of the formula (I) is:

9-cyclopentyl-5,6-dihydro-7-ethyl-3-phenyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopenyl-5,6-dihydro-7-ethyl-3-(furan-2-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(4-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(3-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3-benzyl-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-propyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3,9-dicyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3-(*tert*-butyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methoxyphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(thien-2-yl)-9*H*-pyrazolo[3,4-*c*]1,2,4-triazolo[4,3-*a*]pyridine;

3-(2-chlorophenyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-iodophenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-trifluoromethylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine; or
5,6-dihydro-7-ethyl-9-(4-fluorophenyl)-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine; or a pharmaceutically acceptable salt thereof.

24. (New) A method of claim 14 or 22 wherein the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine or 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine or a pharmaceutically acceptable salt thereof.

25. (New) A method of claim 14 or 22 wherein the adrenergic β2 receptor agonist is selected from salmeterol, formoterol or a pharmaceutically acceptable salt thereof.

26. (New) A method of claim 14 or 22 wherein:
the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine, or a pharmaceutically acceptable salt thereof, and the adrenergic β2 receptor agonist is salmeterol, or a pharmaceutically acceptable salt thereof;
the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine, or a pharmaceutically acceptable salt thereof, and the adrenergic β2 receptor agonist is formoterol, or a pharmaceutically acceptable salt thereof;
the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine, or a pharmaceutically acceptable salt thereof, and the adrenergic β2 receptor agonist is salmeterol, or a pharmaceutically acceptable salt thereof; or

the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine, or a pharmaceutically acceptable salt thereof, and the adrenergic β2 receptor agonist is formoterol, or a pharmaceutically acceptable salt thereof.

27. (New) A method of any one of claims 14 or 22 wherein said selective PDE4 inhibitor and said adrenergic β2 receptor agonist are administered simultaneously, sequentially or separately.

28. (New) A method of claim 14 wherein said obstructive airways disease is asthma, acute respiratory distress syndrome, chronic pulmonary inflammatory disease, bronchitis, chronic bronchitis, chronic pulmonary obstructive disease (COPD),silicosis, allergic rhinitis or chronic sinusitis.

29. (New) A method of claim 28 wherein said obstructive airways disease is chronic obstructive pulmonary disease (COPD).

30. (New) A device of claim 16 wherein the selective PDE4 inhibitor of the formula (I) is:

9-cyclopentyl-5,6-dihydro-7-ethyl-3-phenyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopenyl-5,6-dihydro-7-ethyl-3-(furan-2-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(4-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(3-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3-benzyl-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-propyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3,9-dicyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

3-(*tert*-butyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methoxyphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(thien-2-yl)-9*H*-pyrazolo[3,4-*c*]1,2,4-triazolo[4,3-*a*]pyridine;

3-(2-chlorophenyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-iodophenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-trifluoromethylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine; or
5,6-dihydro-7-ethyl-9-(4-fluorophenyl)-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine; or a pharmaceutically acceptable salt thereof.

31. (New) A device of claim 16 wherein the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine or 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine or a pharmaceutically acceptable salt thereof.

32. A device of claim 16 wherein the adrenergic β2 receptor agonist is selected from salmeterol, formoterol or a pharmaceutically acceptable salt thereof.

33. A device of claim 16 wherein:
the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine, or a pharmaceutically acceptable salt thereof, and the adrenergic β2 receptor agonist is salmeterol, or a pharmaceutically acceptable salt thereof;
the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine, or a pharmaceutically acceptable salt thereof, and the adrenergic β2 receptor agonist is formoterol, or a pharmaceutically acceptable salt thereof;

the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine, or a pharmaceutically acceptable salt thereof, and the adrenergic β2 receptor agonist is salmeterol, or a pharmaceutically acceptable salt thereof; or

the selective PDE4 inhibitor of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine, or a pharmaceutically acceptable salt thereof, and the adrenergic β2 receptor agonist is formoterol, or a pharmaceutically acceptable salt thereof.

A Notice of Allowance is courteously solicited.

Respectfully Submitted,

Date: December 16, 2003

Robert T. Ronau
Attorney for Applicants
Reg. No. 36,257

Pfizer Inc.
Patent Department
Eastern Point Road
Groton, Connecticut 06340
860-441-5910